observed upon initiation of anti-hyperuricemic therapy, due to changing serum uric acid levels resulting
The average molecular weight of pegloticase (tetrameric enzyme conjugated to mPEG) is
Reddening of the face, itching, hives, rash, or feeling warm. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. and that medications to help reduce flares may need to be taken regularly for the first few months
I was terrified. KRYSTEXXA is not recommended if you have high levels of uric acid without a history of gout. Infusion reactions are thought to result from release of various mediators, such as
consists of recombinant modified mammalian urate oxidase (uricase) produced by a genetically
Inject into a single 250
Take these medicines as directed by your doctor or nurse. Even if you’re taking medicine to manage your gout, it can spin out of control and put you at risk of ongoing symptoms and long-term damage. Even with oral gout medicines, some people can’t get their uric acid level low enough to dissolve the uric acid crystal buildup responsible for gout flares and damage. and older. dose (10 mg/kg in dogs) approximately 30 times the MRHD, but were absent at doses (≤ 1.5 mg/kg)
breathing), flushing, chest discomfort, chest pain, and rash. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. KRYSTEXXA in a vial or in an intravenous infusion fluid should never be subjected to artificial heating (e.g., hot water, microwave). KRYSTEXXA is a prescription medicine used in adults to help reduce the signs and symptoms of gout that are not controlled by other treatments. cytoplasmic vacuoles included the spleen, adrenal gland, liver, heart, duodenum, and jejunum. KRYSTEXXA® (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of
Krystexxa is a prescribed medicine that claims to reduce the signs and symptoms of gout that are not regulated by other means of treatment or people who still have high uric acid levels after taking some other medicines. drugs (NSAIDs) or colchicine, or both, beginning at least one week before KRYSTEXXA treatment
The genotoxic potential of pegloticase has not been evaluated. other identifiable cause. Take these medicines as directed by your doctor or nurse. another drug, and may not predict the rates observed in a broader patient population in clinical practice. Do not administer as an intravenous push or bolus. Inform patients not to take KRYSTEXXA if they have a condition known as G6PD deficiency. No studies of interactions of KRYSTEXXA with other drugs have been conducted. There was no evidence of impairment on fertility at pegloticase doses up to 40 mg/kg (approximately 50
The duration of suppression of
KRYSTEXXA therapy. KRYSTEXXA is supplied in a single-dose 2 mL glass vial
dose administered. However, decreases in mean fetal and pup body weights were
during the period of organogenesis at doses up to approximately 50 and 75 times the maximum
No controlled trial data are available on the safety and efficacy of re-treatment with KRYSTEXXA
Uricase is covalently conjugated to monomethoxypoly
Administer KRYSTEXXA in a healthcare setting and
patients in the clinical trials experienced exacerbation. Vacuoles in the spleen, liver, duodenum, and jejunum were within macrophages and most likely
A pooled analysis of data from
KRYSTEXXA is intended for intravenous infusion. mPEG), 2.18 mg Disodium Hydrogen Phosphate Dihydrate (Na2HPO4•2H2O), 8.77 mg Sodium
No formal studies were conducted to examine the effects of either renal or hepatic impairment on
Since infusion
Your doctor or nurse should watch you for any signs of a serious allergic reaction during, and after your treatment with KRYSTEXXA. the reported frequency may be an underestimate. The population pharmacokinetic analysis showed that age, sex, weight, and
while taking KRYSTEXXA. tophi. for Injection to deliver 8 mg of pegloticase (as uricase protein). (ethylene glycol) [mPEG] (10 kDa molecular weight). See additional information. The effect of treatment on tophi was a secondary efficacy endpoint and was assessed using
the maximum medically appropriate dose or for whom these drugs are contraindicated. However it is recommended that diluted solutions be stored
Because these reactions are reported voluntarily from a population of uncertain size, it is not always
disease (18%), arrhythmia (16%), and cardiac failure/left ventricular dysfunction (12%). younger patients, but greater sensitivity of some older individuals cannot be ruled out. every 4 weeks, compared to 5% of patients treated with placebo. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated. population, the estimated background risk of major birth defects and miscarriage in clinical recognized
pregnancies is 2% to 4% and 15% to 20%, respectively. No cases were reported in placebo-treated patients. during and after administratio n of KRYSTEXXA (5.1, 5.2). patients on the importance of adhering to any prescribed medications to help prevent or lessen
Your doctor or nurse should watch you for any signs of a serious allergic reaction during and after your treatment with Krystexxa. The percentages of patients with
Compared to Placebo. Please see the medication guide and prescribing information for more information. mg/dL; had symptomatic gout with at least 3 gout flares in the previous 18 months or at least 1 gout
cytokines. The following serious adverse reactions are discussed in greater detail in other sections of the label: The data described below reflect exposure to KRYSTEXXA in patients with chronic gout refractory to
Your diaphragm is the muscle just below your lungs. During pre-marketing clinical trials, anaphylaxis was reported with a frequency of 6.5% (8/123) of
In the adrenal
Even when your flare ends, uric acid crystals from gout continue to build up, settle in your joints, and potentially damage your bones. Due to the immunogenicity of KRYSTEXXA,
syringe. KRYSTEXXA (pegloticase) is a prescription medicine for adults who have tried other gout medicines and still have high uric acid and gout symptoms. given as an intravenous infusion every two weeks. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis. Vacuoles
T-Mobile. However, delayed type hypersensitivity reactions have also been reported. Krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose … Significant covariates included in the model for determining clearance and volume of distribution
studies, 34% (29 of 85) were 65 years of age and older and 12% (10 of 85) were 75 years of age
for subjects in the KRYSTEXXA groups were 0.7 mg/dL for the KRYSTEXXA 8 mg every 2
METHEMOGLOBINEMIA. Advise
Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA. The following adverse reactions have been identified during postapproval use of KRYSTEXXA. Your doctor or nurse should watch you for any signs of a serious allergic reaction during and after your treatment with KRYSTEXXA. pegloticase pharmacokinetics. Your doctor will also test your uric acid levels prior to each treatment to monitor your response to KRYSTEXXA. was 33 kg/m2, mean duration of gout was 15 years, and mean baseline SUA was 10 mg/dL. KRYSTEXXA 8 mg every 4 weeks, and placebo, respectively. To assess the efficacy of KRYSTEXXA in lowering uric acid, the primary endpoint in both trials was
The risk of infusion reaction is higher in patients whose uric acid level increases to above 6 mg/dL,
Revised: July 2018. Would you like to continue? Only 1/3 of the uric acid in your body that causes gout to spin out of control comes from what you eat. undetectable or low antibody titers. titer: 53% (16 of 30) in the KRYSTEXXA every 2 weeks group compared to 6% in patients who had
KRYSTEXXA 8 mg every 2 weeks or every 4 weeks or placebo in a 2:2:1 ratio. Data obtained from you in connection with this SMS service may include your cell phone number, your carrier’s name and the date, time and content of your messages. mammalian sequences. Your doctor should test you for G6PD before you start KRYSTEXXA. It is not known if KRYSTEXXA passes into your breast milk. Advise the patient to read the FDA-approved patient labeling (Medication Guide). KRYSTEXXA 8 mg every 4 weeks, and placebo, respectively. This pre-treatment may have blunted or obscured symptoms or signs of anaphylaxis
with a Teflon® coated (latex-free) rubber injection stopper to deliver KRYSTEXXA as 8 mg of
regimen was associated with increased frequency of anaphylaxis and infusion reactions and less
Alerts sent via SMS may not be delivered if the mobile phone is not in range of a transmission site, or if sufficient network capacity is not available at a particular time. weeks group. post-infusion should be considered [see WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS]. trials: 85 patients were treated with KRYSTEXXA 8 mg every 2 weeks; 84 patients were treated with
Subjects Who Met
the proportion of patients who achieved plasma uric acid (PUA) less than 6 mg/dL for at least 80% of
Before administration, allow the diluted solution of KRYSTEXXA to reach room temperature. treated with KRYSTEXXA 8 mg every 2 weeks are provided in Table 1. Because of the risk of
In the event of an infusion
blunt the rise of serum uric acid levels, it is recommended that before starting KRYSTEXXA patients
In the US general
the possibility that concomitant use of oral urate-lowering therapy and KRYSTEXXA may potentially
This link will take you to a site maintained by a third party who is solely responsible for its contents. Adverse Reactions Occurring in 5% or More of Patients Treated with KRYSTEXXA
Monitoring Therapy: The risk of anaphylaxis and infusion reactions is higher in patients who have
doses up to 50 and 75 times, respectively, the maximum recommended human dose (MRHD). anaphylaxis. It went completely down to zero for my entire KRYSTEXXA treatment and then it slowly built back up to normal from there. saline. Each uricase subunit has a molecular weight of approximately 34 kDa per
After that, you receive an 8mg infusion of Krystexxa intravenously. represented phagocytic removal of pegloticase from the circulation.